RxDoctor Payments Data

Ann Henderson

Nurse Practitioner · Columbia, MDNPI 1720054620

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.2% of the total across 541 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 9.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $4,545 and has fallen 58.7% since, to $1,876 in 2025. Among nurse practitioner clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,149in general payments, 2019–2025

Across 541 payments — averaging $26.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Novartis$1K
  • AstraZeneca$871
  • Daiichi Sankyo Inc.$634
  • Merck$628
  • AbbVie$542
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$13,33394%
  • Education$8166%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)51$1,351
Novartis50$1,101
AstraZeneca(2 entities)24$871
Daiichi Sankyo Inc.29$634
Merck35$628
AbbVie17$542
Seagen Inc.24$522
Pfizer22$409
E.r. Squibb & Sons, L.L.C.11$404
Eisai Inc.23$389
Puma Biotechnology, Inc.12$349
Takeda Pharmaceuticals U.S.A., Inc.12$328
Rigel Pharmaceuticals, Inc.11$327
Genentech USA, Inc.15$303
GSK11$283
Lilly USA, LLC10$266
Incyte Corporation10$256
Bristol Myers Squibb12$241
Sanofi9$240
Regeneron Healthcare Solutions, Inc.10$231
AVEO Pharmaceuticals, Inc.6$221
Sobi, Inc6$220
Bayer10$216
Pharmacyclics LLC, An Abbvie Company9$214
Exelixis Inc.8$175
Sage Therapeutics, LLC2$174
Pharmaessentia USA Corporation7$171
Boehringer Ingelheim2$137
Ipsen Biopharmaceuticals, Inc5$128
ADC Therapeutics America, Inc.5$126
Beigene USA, Inc.4$124
Mirati Therapeutics, Inc.4$124
ARS Pharmaceuticals Operations, Inc.1$122
Gilead(2 entities)5$120
Alkermes, Inc.1$120
Teva Pharmaceuticals USA, Inc.1$120
Taiho Oncology, Inc.5$119
Coloplast1$112
Amgen1$110
Global Blood Therapeutics, Inc.5$109
Neurocrine Biosciences, Inc.1$108
Morphosys, US Inc.5$105
Axsome Therapeutics, Inc.1$105
Idorsia Pharmaceuticals US Inc1$101
Sanofi-aventis U.S. LLC1$96
Insmed, Inc.1$93
Astellas Pharma US Inc5$90
Recordati_rare_diseases_inc.2$71
Genmab U.S., Inc.2$68
Karyopharm Therapeutics Inc.3$67
Kyowa Kirin, Inc.3$62
Stemline Therapeutics Inc.3$60
Array Biopharma Inc4$58
Immunogen, Inc.2$54
Servier Pharmaceuticals LLC3$45
Epizyme, Inc.2$42
Alnylam Pharmaceuticals Inc.3$38
Myriad Genetic Laboratories, Inc.2$35
Shield Therapeutics Inc1$28
Janssen Scientific Affairs, LLC1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,149 in reported general payments places this provider in the 95th percentile of 1,562 nurse practitioner providers in Maryland.

See all nurse practitioner providers in Maryland

Medicare billing

Part B allowed, 2024
$14,335
Medicare patients
139
Services billed
168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide20$227,069
ImbruvicaIbrutinib11$178,949
EliquisApixaban57$47,487
Anastrozole41$905
Hydroxyurea30$840
Duloxetine Hcl13$803
Olanzapine28$729
Tamoxifen Citrate11$649
Letrozole22$547
Levofloxacin13$476
Ondansetron Hcl45$465
Gabapentin41$441
Oxycodone Hcl35$423
Mirtazapine18$366
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen34$326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$214$178,94911 claims
PfizerEliquis$409$47,48757 claims
Lilly USA, LLCOlanzapine$266$72928 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$120$14713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,562 nurse practitioner providers in Maryland.

Other nurse practitioner in Columbia

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →